Berry Genomics
Berry Genomics is a company specializing in developing and commercializing technologies for life sciences and clinical applications.
Berry Genomics, founded in May, 2010 and headquartered in Chengdu, is a gene sequencing in the field of clinical translation company. The founder is Gao Yang. Listed on the SZSE on April 22, 1997, the company's major shareholders are Gao Yang, Chengdu Tianxing Instrument and Meter Co.,Ltd. and Tianjin Junruiqi Equity Investment Partnership (LP). Rivals that have direct and indirect competition with Berry Genomics include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Berry gene signed a contract with inmana to deepen cooperation in the field of gene sequencer
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
The early-stage cancer-detection technology has declared its mission: to take on and defeat the fatal illness, for the benefit of humanity. Following Burning Rock and Genetron Health, the US biotech GRAIL looks to go public on Nasdaq.
Sep 10, 2020 11:48 AM
Berry gene: the net profit in the first three quarters is expected to drop by 77% to 83%, and the demand for prenatal testing services is reduced